Greenwich LifeSciences, Inc.

GLSI Healthcare Biotechnology

In the quarter to June 2026, EPS grew 10.0% and free cash flow grew 13.1%, each against the same quarter a year earlier. Insiders bought in the last twelve months.

14.55 0.77 −5.03%
Market cap
$224.9M
P/E
0.0×
Fwd P/E
—
Dividend yield
—
F-score
n/a
Altman Z
n/a
Beneish M
n/a
Dividend safety
n/a
Jun '26 Mar '26 Dec '25 Sep '25 Older periods
ROE
(986.31%) (676.66%) (3,068.35%) (566.73%)

+8 more TTM periods

ROA
(374.46%) (336.00%) (376.92%) (421.74%)
ROIC
0.00% 0.00% 0.00% 0.00%
Return on Tangible Assets
(720.90%) (422.57%) (5,480.80%) (929.56%)
Free Cash Flow per Share
(0.85) (0.88) (0.73) (0.63)
Free Cash Flow
(12.49) (12.78) (9.91) (8.59)
Other line items

Show all line items

Columns are period end dates